BioRegenx Changes Auditors
Ticker: BRGX · Form: 8-K · Filed: May 16, 2024 · CIK: 1593184
| Field | Detail |
|---|---|
| Company | Bioregenx, INC. (BRGX) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
BioRegenx swapped accounting firms, bringing in MaloneBailey, LLP.
AI Summary
BioRegenx, Inc. announced on May 15, 2024, that it has dismissed its former independent registered public accounting firm, BF Borgers CPA, PC. The company has appointed MaloneBailey, LLP as its new independent registered public accounting firm, effective May 15, 2024.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.
Risk Assessment
Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial restatements or other disclosures that may impact the company's valuation.
Key Players & Entities
- BioRegenx, Inc. (company) — Registrant
- BF Borgers CPA, PC (company) — Former independent registered public accounting firm
- MaloneBailey, LLP (company) — New independent registered public accounting firm
- May 15, 2024 (date) — Date of dismissal and appointment
FAQ
When was the change in independent registered public accounting firm effective?
The change was effective May 15, 2024.
Who was BioRegenx, Inc.'s former independent registered public accounting firm?
BioRegenx, Inc.'s former independent registered public accounting firm was BF Borgers CPA, PC.
Who is BioRegenx, Inc.'s new independent registered public accounting firm?
BioRegenx, Inc.'s new independent registered public accounting firm is MaloneBailey, LLP.
Did the former accountant report any disagreements with BioRegenx, Inc.?
The filing states that the principal accountant's reports on the financial statements for the past two fiscal years did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit basis, or scope of the audit.
Did BioRegenx, Inc. consult with the new accountant before engaging them?
The filing indicates that BioRegenx, Inc. did not consult with Malone Bailey, LLP prior to their engagement.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 13.6 · Accepted 2024-05-16 16:29:03
Filing Documents
- bioregenx_8k.htm (8-K) — 20KB
- 0001683168-24-003582.txt ( ) — 181KB
- fdit-20240515.xsd (EX-101.SCH) — 3KB
- fdit-20240515_lab.xml (EX-101.LAB) — 33KB
- fdit-20240515_pre.xml (EX-101.PRE) — 22KB
- bioregenx_8k_htm.xml (XML) — 3KB
01 Changes
Item 4.01 Changes in Registrant's Certifying Accountants. (a) Termination of Independent Registered Public Accounting Firm On May 15, 2024, BioRegenx, Inc. (the "Company") dismissed BF Borgers CPA PC ("BF Borgers") as its independent registered public accounting firm. The Company's audit committee unanimously approved the decision to dismiss BF Borgers. There have been no "disagreements" (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K) and no "reportable event" occurred (as that term is defined in Item 304(a)(1)(v) of Regulation S-K during the fiscal year ended December 31, 2023 and the subsequent interim period up to and including the date of BF Borgers' dismissal between the Company and BF Borgers on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which, if not resolved to the satisfaction of BF Borgers, would have caused them to make reference to the subject matter of the disagreement in connection with their report on the Company's financial statements for those periods. BF Borgers is not currently permitted to appear or practice before the Commission, as a result, we are not requesting BF Borgers to furnish our Company with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioRegenx, Inc. (Registrant) Date: May 16, 2024 By: /s/ William Resides Name: William Resides Title: Chief Executive Officer 2